Product Images Fetzima

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Fetzima NDC 0456-2220 by Allergan, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

fetzima 01

fetzima 01

fetzima 02

fetzima 02

This is a list of drugs and their interactions. It includes information about drugs that inhibit or induce certain enzymes, such as CYP3A, as well as drugs that act as substrates for these enzymes. The table shows the average maximum concentration (Cmax) and fold change for different drugs, as well as their 90% confidence intervals. However, without additional context or labels, it is difficult to provide specific details about the drugs or their effects.*

fetzima 03

fetzima 03

This appears to be a data table with information on the population's age, gender, renal impairment, and hepatic impairment. It also includes PK data with parameters such as Cmax and AUC, as well as fold change and 90% Cl. Without additional context or a clear indication of what this data pertains to, it is difficult to provide a more specific description.*

fetzima 04

fetzima 04

fetzima 05

fetzima 05

This appears to be a label for the medication Fetzima, a capsule containing 20mg of levomilnacipran hydrochloride which is used to treat depression. The label includes information for storage at 25°C, pricing, and a note to give a medication guide to each patient. The medication is manufactured by Pierre Fabre Medicament and distributed by Allergan.*

fetzima 06

fetzima 06

Each capsule of Fetzima contains 45.9 mg of levomilnacipran. It is an extended-release capsule that should be swallowed whole and not chewed or crushed. It is recommended to store the drug at 25°C (77°F) and keep it away from children. The usual dosage should be taken by following the enclosed guide provided to each patient. The drug is licensed by Allergan and distributed by Allergan USA Inc.*

fetzima 07

fetzima 07

Each capsule of this medication contains 80mg of levominacpran hydrochloride, also identified as Fetzima. It is an extended-release capsule that must be swallowed whole, avoiding chewing or crushing. This medication needs to be stored between 15-30°C (50-86°F), avoiding excessive heat between 25°C (77°F) and controlled room temperature. In case of prescription, it is essential to dispense the accompanying medication guide to each patient. It is a medication marketed by Allergan.*

fetzima 08

fetzima 08

This is a medication called Fetzima, which is an extended-release capsule containing 20mg of levomilnacipran. Each capsule contains 137.8mg of levomilnacipran hycrochlorde equivalent to 120mg of levomilnacipan. The recommended usage and other details can be found in the full prescribing information. The medication guide accompanying the product should be dispensed to each patient. The drug should be swallowed whole and not chewed or crushed. It should be stored at room temperature and kept out of the reach of children. Made in France, licensed from Pere Fabr, and distributed by Allergan USA in Madison, NJ.*

fetzima 09

fetzima 09

This is a description of a product called "Titration Pack", which includes a medication called Fetzima in capsule form. The pack also includes other capsules with the label "Exknded-Kase Capsules", but no further information is provided on what they are for. The Fetzima capsules have a strength of 20mg and there are two types of capsules included: "ey sis & g capsules" and "Pritere Erisreetray" capsules. The product is associated with a company called Allergon.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.